Market Overview
According to the fortune business insights, the global fusion biopsy market size was valued at USD 793.5 million in 2025. The market is projected to grow from USD 852.1 million in 2026 to USD 1,546.7 million by 2034, exhibiting a CAGR of 7.7% during the forecast period. North America dominated the global fusion biopsy market with a market share of 34.04% in 2025.
The analysis shows that market growth is attributed to the increasing demand for accurate diagnosis of prostate cancer. Healthcare professionals increasingly prefer fusion biopsy, which combines MRI and ultrasound imaging, for its high precision in guiding needles to targeted areas for tissue sampling. This trend indicates a strong and growing demand for advanced diagnostic procedures worldwide.
Major Players Profiled in the Market Report:
Segments
Increasing Installation of Advanced Systems to Propel Equipment Segment Growth
Based on product, the market is classified into equipment and consumables. The equipment segment holds the largest market share owing to the increasing installation of fusion biopsy systems in emerging countries and the higher adoption of fully integrated, AI-powered platforms in developed nations.
Long-Standing Clinical Adoption to Drive Transrectal Segment Expansion
By procedure, the market is categorized into transrectal and transperineal. The transrectal segment is leading the market due to its long-standing clinical adoption, well-established workflow, and lower procedural complexity compared to the transperineal approach.
High Procedure Volume to Dominate the Hospitals Segment
Based on end-user, the market is segmented into hospitals, diagnostic centers, and others. The hospitals segment holds the largest market share as these facilities serve as primary centers for prostate cancer diagnosis, handle the highest patient volumes, and have the advanced imaging infrastructure required for fusion biopsy.